Top results not only in the medical field – study highlights Charité’s economic importance

Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and Actinium Pharmaceuticals, Inc. announced that they have entered into an agreement for the supply of Actinium-225 (Ac-225). With this agreement, Actinium Pharmaceuticals will have access to Eckert &…

The loss of muscle mass and strength poses an increasingly significant challenge for an ageing society. Prof. Kristina Norman's team at the German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE) has now shown that amino acid profiles could…

AMBOSS, the leading resource for medical education and clinical decision-making in Germany and the US, closes a €240M financing round with new long-term investors, supporting the exploration of additional international markets and the expansion of…

Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and AtomVie Global Radiopharma Inc. (AtomVie) today announced a global supply agreement. Eckert & Ziegler will provide its high-quality non-carrier added Lutetium-177 chloride (n.c.a. Lu-177,…

A study at Charité – Universitätsmedizin Berlin has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine fails to offer sufficient…

Application period ends on May 28

Joint press release by Charité and Max Delbrück Center

Nature study: MIS-C traced to reactivation of the Epstein-Barr virus

Are technology parks becoming obsolete in an era of hybrid work? Not at all. Head to Adlershof to experience how tech hubs bring together smart minds to create thriving companies.